ROLE OF TOPIRAMATE IN TREATMENT OF EPILEPSY
Abstract
The review summarizes modern data on efficacy, safety and role of topiramate in treatment of epilepsy. Pharmacokinetic and pharmacodynamiccharacteristics of the medicine are presented in the article. The role of topiramate in epilepsy treatment with accounts to its pharmacoenomic values and modern requirements to antiepileptic drugs is determined. Based on presented data conclusion on topiramate efficacy in treatment of various forms of epilepsy in children and adults used both in mono- as well as in combined therapy can be done.
About the Author
S. G. Burd
The Russian State Medical University named after N.I. Pirogov (Moscow)
Russian Federation
Russian Federation
References
1. Aldenkamp AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia. 2003; 44 Suppl. 4: 21-9
2. Arroyo S, Dodson WE, Privitera MD, et al. Randomized dose controlled study of topiramate as first-line therapy in epilepsy. ActaNeurolScand. 2005 Oct; 112 (4): 214-22
3. Battino D, Croci D, Rossini A, et al. Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. ClinPharmacokinet. 2005; 44 (4): 407-16
4. Ben-Menachem E, Axelsen M, Johanson EH, et al. Predictors of weight loss in adults with topiramate-treated epilepsy. ObesRes. 2003 Mar; 11 (3): 556-62
5. Besag FMC. Behavioural effects of the new anticonvulsants. DrugSaf. 2001; 24 (7): 513-36
6. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. ClinPharmacokinet. 2004; 43 (12): 763-80
7. Biton V, Edwards KR, Montouris GD, et al. Topiramate titration and tolerability. Ann Pharmacother. 2001 Feb; 35 (2): 173-9
8. Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs. 2003; 17 (11): 781-91
9. Brunbech L, Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review ofnewer versus older agents. Drugs. 2002; 62 (4): 593-604
10. Coppola G. Treatment of partial seizures in childhood: an overview. CNS Drugs. 2004; 18 (3): 133-56
11. Deckers CLP, Knoester PD, de Haan GJ, et al. Selection criteria for the clinical use of the newer antiepileptic drugs. CNS Drugs. 2003; 17 (6): 405-21
12. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs: I. Treatment of newonset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2004 May; 45 (5): 401-9
13. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs: II. Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2004 May; 45 (5): 410-23
14. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidencebased analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006 Jul; 47 (7): 1094-120
15. Glier C, Dzietko M, Bittigau P, et al. Therapeutic doses of topiramate are not toxic to the developing rat brain. ExpNeurol. 2004; 187 (2): 403-9
16. Guerrini R, Carpay J, Groselj J, et al. Topiramatemonotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting. Seizure. 2005 Sep; 14 (6): 371-80
17. Guerrini R, Parmeggiani L. Topiramate and its clinical applications in epilepsy. Expert OpinPharmacother. 2006; 7 (6): 811-23
18. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci/ 2004; 5(7): 553-64.
19. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000; 41 (1):3-9.
20. White HS. Mechanism of action of newer anticonvulsants. J Clin Psychiatry. 2003; 64 (8):5-8.
21. Johannessen SI. Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. Epilepsia. 1997; 38 Suppl. 1: S18-23
22. Kockelmann E, Elger CE, Helmstaedter C. Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication. Epilepsy Behav. 2004; 5 (5): 716-21
23. Langtry HD, Gillis JC, Davis R. Topiramate: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs. 1997 Nov; 54 (5): 752-73
24. LaRoche SM. A new look at the secondgeneration antiepileptic drugs: a decade of experience. Neurologist. 2007 May; 13 (3): 133-9
25. Marson AG, Al-KharusiAM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblindedrandomised controlled trial. Lancet. 2007 Mar 24; 369 (9566): 1016-26
26. Marson AG, Al-KharusiAM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblindedrandomised controlled trial. Lancet. 2007 Mar 24; 369 (9566): 1000-15
27. Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. DrugSaf. 2007; 30 (7): 555-67
28. Mula M, Trimble MR, Lhatoo SD, et al. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia. 2003; 44 (5): 659-63
29. Palmieri C, Canger R. Teratogenic potential of the newer antiepileptic drugs: what is known and how should this influence prescribing? CNS Drugs. 2002; 16 (11): 755-64
30. Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. ClinPharmacokinet. 2006; 45 (4): 351-63
31. Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. ActaNeurolScand. 2003 Mar; 107 (3): 165-75
32. Reiter E, Feucht M, Hauser E, et al. Changes in body mass index during long-term topiramate therapy in paediatric epilepsy patients: a retrospective analysis. Seizure. 2004 Oct; 13 (7): 491-3
33. Rema´k E, Hutton J, Selai CE, et al. A costutility analysis of adjunctive treatment with newer antiepileptic drugs in the UK. J DrugAssess. 2004; 7 (2): 109-20
34. Richard D, Ferland J, Lalonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition. 2000; 16 (10): 961-6
35. Sachdeo RC, Sachdeo SK, Levy RH, et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia. 2002 Jul; 43 (7): 691-6
36. Selai CE, Trimble MR, Price MJ, et al. Evaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugs. CurrMedResOpin. 2005 May; 21 (5): 733-9
37. Shank RP, Gardocki JF, Streeter AJ, et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000; 41 Suppl. 1: S3-9
38. Topamax 25mg, 50mg, 100mg, 200mg tablets and sprinkle capsule 15, 25 or 50 mg: summary of product characteristics. High Wycombe, UK: Janssen-Cilag Ltd. 2006 Nov
39. TopamaxR (topiramate tablets and sprinkle capsules): US prescribing information. Titusville (NJ): Ortho-McNeil Neurologics Inc. 2007 Mar
40. Guberman A, Neto W, Gassmann-Mayer C, et al. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. ActaNeurolScand. 2002 Oct; 106 (4): 183-9 41. Sivkova SN, Milovanova OA, Zaĭkova FM., Optimization of treatment focal forms of epilepsy in young children ZhNevrolPsikhiatrIm S Korsakova. 2011; 111(9):43-7. Russian.
41. Watanabe T, Oyanagi R, Minagawa K. No ToHattatsu. Shory-term and long-term efficacy of topiramate in refractory generalized epilepsy of children. 2011 May; 43(3):223-7. Japanese.
Review
For citations:
Burd S.G. ROLE OF TOPIRAMATE IN TREATMENT OF EPILEPSY. Epilepsy and paroxysmal conditions. 2012;4(1):34-39. (In Russ.)
Views: 562
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
